Rapid liquid chromatography tandem mass spectrometry determination of rivaroxaban levels in human plasma for therapeutic drug monitoring

Varga, Andreea; Șerban, Răzvan Constantin; Muntean, Daniela Lucia; Tătar, Cristina Maria; Farczádi, Lénárd; Ţilea, Ioan

doi:10.1515/rrlm-2017-0007

Cited by 11 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 38 In our study group, hypertensive patients receiving FDCs had significantly better adherence with clear evidence in 2014, probably encouraged by their wide use, as a direct consequence of relevant results in therapeutic and drug-monitoring studies. 39 …”

Section: Discussionmentioning

confidence: 99%

Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania

Ţilea

Petra

Voidăzan

et al. 2018

PPA

Self Cite

View full text Add to dashboard Cite

PurposeThis study was performed to elucidate the level of adherence to antihypertensive treatment in adult subjects attending a family medicine clinic in a city in central Romania.Patients and methodsA cross-sectional, retrospective study was performed on a cohort of hypertensive adults. A total of 525 participants were selected from 1,714 adults attending a single urban family medicine practice. Assessment of adherence to therapy was performed by a chart review of prescription and clinical records over a 4-year study period.ResultsThe results showed that 69.8% of the patients had high adherence (>80% with therapy); 20.3% had medium adherence (20%–79%); and 9.9% had low adherence (<20%). A positive association was found (p = 0.01) between low adherence and male gender. A significant positive association (p = 0.02) was found between total cardiovascular risk and level of adherence. We found that 54.7% of the high adherence subjects had well-controlled blood pressure, and chronic kidney disease was associated with high adherence to therapy (p = 0.03). Antihypertensive regimens administered as fixed-dose combinations were positively associated with high adherence (p = 0.001). Subjects who had their antihypertensive regimen adjusted to a new drug class during the study period showed enhanced adherence compared to subjects treated with an unchanged regimen (p = 0.001).ConclusionThis is the first published study assessing adherence to antihypertensive therapy in family medicine practice in Romania. It presented data derived from a primarily urban setting and targeted a geographical area where the prevalence of hypertension has increased continuously. Female gender, age, presence of cardiovascular risk factors, defined cardiovascular disease, chronic renal impairment, and good control of hypertension were positively associated with high adherence. The results provide insights to guide further strategies to improve adherence and indirect methods for blood pressure management strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania

Ţilea

Petra

Voidăzan

et al. 2018

PPA

Self Cite

View full text Add to dashboard Cite

show abstract

“…The development of new, high-technology laboratory methods continues to improve therapy monitoring, as well as diagnostic and prognostic accuracy in cardiovascular medicine [ 36 , 82 ]. With the advent of novel molecular biology techniques, evaluation of the entire molecular chain, from DNA to RNA, proteins, and metabolites has become possible.…”

Section: A Glimpse Into the Future—emerging Molecular Candidate Biomarkers For Acute Myocardial Infarctionmentioning

confidence: 99%

Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction—Promises and Challenges

Ţilea

Varga

Șerban³

2021

Diagnostics

Self Cite

View full text Add to dashboard Cite

Despite important advancements in acute myocardial infarction (AMI) management, it continues to represent a leading cause of mortality worldwide. Fast and reliable AMI diagnosis can significantly reduce mortality in this high-risk population. Diagnosis of AMI has relied on biomarker evaluation for more than 50 years. The upturn of high-sensitivity cardiac troponin testing provided extremely sensitive means to detect cardiac myocyte necrosis, but this increased sensitivity came at the cost of a decrease in diagnostic specificity. In addition, although cardiac troponins increase relatively early after the onset of AMI, they still leave a time gap between the onset of myocardial ischemia and our ability to detect it, thus precluding very early management of AMI. Newer biomarkers detected in processes such as inflammation, neurohormonal activation, or myocardial stress occur much earlier than myocyte necrosis and the diagnostic rise of cardiac troponins, allowing us to expand biomarker research in these areas. Increased understanding of the complex AMI pathophysiology has spurred the search of new biomarkers that could overcome these shortcomings, whereas multi-omic and multi-biomarker approaches promise to be game changers in AMI biomarker assessment. In this review, we discuss the evolution, current application, and emerging blood biomarkers for the diagnosis of AMI; we address their advantages and promises to improve patient care, as well as their challenges, limitations, and technical and diagnostic pitfalls. Questions that remain to be answered and hotspots for future research are also emphasized.

show abstract

“…Consecutively, endothelial dysfunction can be influenced by the drugs that septic patients receive during therapy, not only directed related to sepsis, but also with other associated dysfunctions: anticoagulants, vasoactive, antihypertensives, calcium channel blockers, so endothelial alteration should be evaluated not only in the context of the underlying disease but as well as for the applied therapy [ 14 , 15 ]. Equally important is not only the proper administration but also the biological properties, pharmacokinetics and plasma levels of each of these drugs [ 16 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic and Prognostic Role of Vascular Endothelial Growth Factor C in Sepsis and Septic Shock

Almasy

Szederjesi

Grigorescu

et al. 2020

The Journal of Critical Care Medicine

View full text Add to dashboard Cite

IntroductionVariations in the expression of vascular endothelial growth factor (VEGF) could be used as a biomarker in critically ill patients with sepsis and septic shock. Inflammation potently upregulates VEGF-C expression via macrophages with an unpredictable response. This study aimed to assess one of the newer biomarkers (VEGF-C) in patients with sepsis or septic shock and its clinical value as a diagnostic and prognostic tool.Material and methodsThe study involved 142 persons divided into three groups. Group A consisted of fifty-eight patients with sepsis; Group B consisted of forty-nine patients diagnosed as having septic shock according to the Sepsis -3 criteria. A control group of thirty-five healthy volunteers comprised Group C. Severity scores, prognostic score and organ dysfunction score, were recorded at the time of enrolment in the study. The analysis included specificity and sensitivity of plasma VEGF-C for diagnosis of septic shock. Circulating plasma VEGF-C levels were correlated with the APACHE II, MODS and severity scores and mortality.ResultsThe mean (SD) plasma VEGF-C levels in septic shock patients (1374(789) pg./m), on vasopressors at the time of admission to the ICU, were significantly higher 1374(789)pg./mL, compared the mean (SD) plasma VEGF-C levels in sepsis patients (934(468) pg./mL); (p = 0.0005, Student’s t-test.) Plasma VEGF-C levels in groups A and B were shown to be significantly correlated with the APACHE II (r = 0.21, p = 0.02; r = 0.45, p = 0.0009) and MODS score (r = 0.29, p = 0.03; r = 0.4, p = 0.003). There was no association between plasma VEGF-C levels and mortality [p = 0.1]. The cut-off value for septic shock was 1010 pg./ml.ConclusionsVEGF-C may be used as a prognostic marker in sepsis and septic shock due to its correlation with APACHE II values and as an early marker to determine the likelihood of developing MODS. It could be used as an early biomarker for diagnosing patients with septic shock.

show abstract

Rapid liquid chromatography tandem mass spectrometry determination of rivaroxaban levels in human plasma for therapeutic drug monitoring

Abstract: Abstract

Cited by 11 publications

References 19 publications

Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania

Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania

Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction—Promises and Challenges

The Diagnostic and Prognostic Role of Vascular Endothelial Growth Factor C in Sepsis and Septic Shock

Contact Info

Product

Resources

About